{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:29:05Z","timestamp":1790767745621,"version":"4.1.0"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T00:00:00Z","timestamp":1708128000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014848","name":"Arnold Ventures","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014848","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ejca.2024.113942","type":"journal-article","created":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T11:33:20Z","timestamp":1708169600000},"page":"113942","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Equal censoring but still informative: When the reasons for censoring differ between treatment arms"],"prefix":"10.1016","volume":"201","author":[{"given":"Timoth\u00e9e","family":"Olivier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.ejca.2024.113942_bib1","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1016\/j.ejca.2015.07.005","article-title":"The role of censoring on progression free survival: oncologist discretion advised","volume":"51","author":"Prasad","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.113942_bib2","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ejca.2020.09.031","article-title":"Censored patients in Kaplan\u2013Meier plots of cancer drugs: an empirical analysis of data sharing","volume":"141","author":"Rosen","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.113942_bib3","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jclinepi.2021.07.013","article-title":"Informative censoring due to missing data in quality of life was inadequately assessed in most oncology randomized controlled trials","volume":"139","author":"Olivier","year":"2021","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"10.1016\/j.ejca.2024.113942_bib4","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-020-0368-0","article-title":"Informative censoring - a neglected cause of bias in oncology trials","volume":"17","author":"Templeton","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2024.113942_bib5","unstructured":"Agarwal N., et al. CONTACT-2: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). \u3008https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2024.42.4_suppl.18\u3009."},{"issue":"7172","key":"10.1016\/j.ejca.2024.113942_bib6","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1136\/bmj.317.7172.1572","article-title":"Survival probabilities (the Kaplan-Meier method)","volume":"317","author":"Bland","year":"1998","journal-title":"Bmj 5 d\u00e9c"},{"issue":"6","key":"10.1016\/j.ejca.2024.113942_bib7","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor\u2013positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med 9 f\u00e9vr"},{"key":"10.1016\/j.ejca.2024.113942_bib8","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"13","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2024.113942_bib9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.eururo.2022.08.022","article-title":"Lutetium-177-PSMA-617 in metastatic castration-resistant prostate cancer: limitations of the vision trial","volume":"84","author":"Olivier","year":"2023","journal-title":"Eur Urol"},{"issue":"16_suppl","key":"10.1016\/j.ejca.2024.113942_bib10","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2005.23.16_suppl.1569","volume":"41","author":"Olson","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2024.113942_bib11","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J Clin Oncol 10 janv"},{"issue":"14","key":"10.1016\/j.ejca.2024.113942_bib12","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1200\/JCO.21.02904","article-title":"Frontline dual checkpoint inhibition in metastatic melanoma over anti\u2013PD-1 monotherapy: The case for a comparative randomized controlled trial","volume":"40","author":"Olivier","year":"2022","journal-title":"J. Clin. Oncol."}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924001187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924001187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:43:57Z","timestamp":1760733837000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924001187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":12,"alternative-id":["S0959804924001187"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.113942","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Equal censoring but still informative: When the reasons for censoring differ between treatment arms","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.113942","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"113942"}}